AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $61.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$61.6M netNet selling
- CongressSTOCK Act, last 180 days
- -$1K to -$15K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 9 added, 4 cutMore adding
Key stats
Fundamentals Sep 27- Open
- $677.53
- 52-wk high
- $682.98
- High
- $678.00
- 52-wk low
- $434.50
- Low
- $664.53
- Prev close
- $678.39
- Mkt cap
- $249.58B
- P/E
- 36.4x
- Volume
- 2.10M
- Fwd P/E
- 24.1x
- Beta
- 0.85
- Div yield
- 0.27%
- P/S
- 5.4x
- P/B
- 4.7x
- Profit margin
- +15.0%
- Op margin
- +18.8%
- ROE
- +13.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about TMO filings
Are insiders buying or selling Thermo Fisher Scientific Inc (TMO) stock?
Net selling: insiders sold $61.6M and bought $0 of TMO stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. $50.9M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Casper, Marc N (Chairman & CEO), who sold $32.8M. The latest filing was on Sep 1, 2026.
Which members of Congress have traded TMO recently?
Rep. Dwight Evans (D) sold $1K to $15K on May 7, 2026, disclosed 8 days later. In total, 1 member disclosed 1 TMO trade with trade dates in the last 180 days, filed a median 8 days after trading.
How current is this TMO smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (3)
- VG
Viking Global
$511.7M
added
- GC
Glenview Capital
$191.3M
added
- DS
D.E. Shaw
$172.8M
added
What insiders are doing
What Congress is doing
Sells (2)
How top traders are positioned
No tracked top-trader positions in TMO right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 5.6% above what analysts expected.
Earnings per share
$5.71 expected
Revenue
No comparable estimate
Reports Oct 21, 2026, in 24 days
Estimates as of Sep 27, 2026
EPS expected
$6.33 to $6.56
Revenue expected
20 analysts
Last 30 days
Analysts raising estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $11.12B | $12.21B | $11.01B | $11.99B |
| Cost of what it sold | $6.54B | $7.20B | $6.53B | $7.05B |
| Gross profit | $4.58B | $5.01B | $4.48B | $4.94B |
| What it spent | ||||
| Research and development | $347.0M | $357.0M | $336.0M | $364.0M |
| Sales and admin | $2.16B | $1.98B | $2.18B | $1.91B |
| Other operating costs | — | $374.0M | $96.0M | $583.0M |
| Total operating expenses | $2.51B | $2.71B | $2.61B | $2.86B |
| What was left | ||||
| Operating profit | $2.08B | $2.30B | $1.86B | $2.09B |
| Interest on debt | $347.0M | $365.0M | $354.0M | $401.0M |
| Profit before tax | $1.83B | $2.12B | $1.73B | $1.92B |
| Tax | $207.0M | $153.0M | $70.0M | $167.0M |
| Net profit | $1.62B | $1.98B | $1.65B | $1.74B |
| EBITDA | $2.84B | $3.21B | $2.31B | $2.57B |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Leans bullishSep 26Thermo Fisher Scientific's Building Blocks to 2028 Growth 'Fundamentally Sound,' Deutsche Bank Says
BullishSep 25Advanced Biomed Inc. Common Stock (NYSE: ADVB) Stock Price, News & Analysis
NeutralSep 25Sales fell 13% at Astrotech (ASTC), while its annual loss widened.
NeutralSep 25Thermo Fisher Scientific stock rises 1.64 percent ahead of the open
NeutralSep 25Thermo Fisher Scientific (TMO) Launches CHO K1 Media Suite, Is The Stock Too Pricey?
Leans bearishSep 25After cancer treatment, monitoring may reach patients without tumor tissue
Leans bullishSep 25Biodesix advances MRD testing programs with Bio-Rad, Thermo Fisher
Leans bullishSep 25
Macro
30 macro signals shaping TMO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results